A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subje...
Saved in:
Published in | British journal of clinical pharmacology Vol. 48; no. 3; pp. 367 - 374 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.09.1999
Blackwell Science Blackwell Science Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening.
Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered.
Results No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night.
Conclusions The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration. |
---|---|
AbstractList | To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening.
Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double-blind to 36 healthy subjects under standardized conditions in a six-period, incomplete-block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered.
No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night.
The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration. Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. Results No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. Conclusions The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration. Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at various times before morning awakening. Methods Zaleplon 10 mg, zolpidem 10 mg, or placebo was administered double‐blind to 36 healthy subjects under standardized conditions in a six‐period, incomplete‐block, crossover study. Subjects were gently awakened and given medication at predetermined times 5, 4, 3, or 2 h before morning awakening, which occurred 8 h after bedtime. When the subjects awoke in the morning, a battery of subjective and objective assessments of residual effects of hypnotics was administered. Results No residual effects were demonstrated after zaleplon 10 mg, when administered as little as 2 h before waking, on either subjective or objective assessments, whereas zolpidem 10 mg showed significant residual effects on DSST and memory (immediate and delayed free recall) after administration up to 5 h before waking and choice reaction time, critical flicker fusion threshold and Sternberg memory scanning after administration up to 4 h before waking. Residual effects of zolpidem were apparent in all objective and subjective measurements when the drug was administered later in the night. Conclusions The present results demonstrate that zaleplon at the dose of 10 mg is free of residual hypnotic or sedative effects when administered nocturnally as little as 2 h before waking in normal subjects. In contrast, residual effects of zolpidem are still apparent on objective assessments up to 5 h after nocturnal administration, longer than has been reported from studies involving daytime administration. |
Author | Paty Cevallos Worthington Fruncillo Martin Danjou Unruh |
Author_xml | – sequence: 1 givenname: P surname: DANJOU fullname: DANJOU, P organization: Wyeth-Ayerst Research, Paris, France – sequence: 2 givenname: I surname: PATY fullname: PATY, I organization: Wyeth-Ayerst Research, Paris, France – sequence: 3 givenname: R surname: FRUNCILLO fullname: FRUNCILLO, R organization: Wyeth-Ayerst, Radnor, United States – sequence: 4 givenname: P surname: WORTHINGTON fullname: WORTHINGTON, P organization: Wyeth-Ayerst Biostatistics, Slough, United Kingdom – sequence: 5 givenname: M surname: UNRUH fullname: UNRUH, M organization: Wyeth-Ayerst, Radnor, United States – sequence: 6 givenname: W surname: CEVALLOS fullname: CEVALLOS, W organization: Wyeth-Ayerst, Radnor, United States – sequence: 7 givenname: P surname: MARTIN fullname: MARTIN, P organization: Wyeth-Ayerst, Radnor, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1922450$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10510148$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1v1DAQhi1URLeFv4B84JowtuN8SAiprPioVAkOcLZmHbvrxbGjOGXbnpD4p_wSnG5Vyo2TrZnnnRm97wk5CjEYQiiDkkFVv96VTNSy4IzLknVdVwIAr8rrJ2T10DgiKxBQF5JLdkxOUtoBMMFq-YwcM5AMWNWuyHRGdRxGnFyKgUZL562hk0muv0JPjbVGz2mp36I3o88Mhp7eRj-63gzURu_j3oVLiv3ggkvzhLPLlKRzpPz3z19bujE2TobiHr-bkNHn5KlFn8yL-_eUfPvw_uv6U3Hx-eP5-uyi0LKuqmJj0NjaYsfaFnmtBYgOmrqrQEiJ0GoDDVTAhcSm3whsWsMbZLppem3aBsUpeXuYO15tBpOLIR_n1Ti5AacbFdGpfzvBbdVl_KF4tkawNg9oDwP0FFOajH3QMlBLDmqnFrvVYrdaclB3OajrLH35ePcj4cH4DLy6BzBp9HbCoF36y3WcVxIy9uaA7Z03N_-9X71bf8kf8QeK06gS |
CODEN | BCPHBM |
CitedBy_id | crossref_primary_10_1520_JFS2002357 crossref_primary_10_1016_j_sleep_2018_06_011 crossref_primary_10_1592_phco_27_1_89 crossref_primary_10_1002_hup_980 crossref_primary_10_1177_875512250101700202 crossref_primary_10_2165_11312920_000000000_00000 crossref_primary_10_5665_sleep_1996 crossref_primary_10_1097_00045391_200305000_00005 crossref_primary_10_1007_s13311_012_0148_3 crossref_primary_10_3389_fnins_2022_893015 crossref_primary_10_1002_hup_500 crossref_primary_10_1007_s00213_012_2756_3 crossref_primary_10_1177_089719000001300409 crossref_primary_10_1002_hup_986 crossref_primary_10_1126_scitranslmed_3005213 crossref_primary_10_1046_j__5251_2001_01520_x crossref_primary_10_1586_ern_11_197 crossref_primary_10_1002_1099_1166_200008_15_8_704__AID_GPS183_3_0_CO_2_S crossref_primary_10_1093_sleep_zsy258 crossref_primary_10_1002_hup_310 crossref_primary_10_1016_j_jsmc_2008_03_001 crossref_primary_10_1016_j_jsmc_2010_09_002 crossref_primary_10_1016_j_jsmc_2010_08_006 crossref_primary_10_1007_s11910_003_0074_1 crossref_primary_10_1177_1941738117743205 crossref_primary_10_1080_13803395_2014_928268 crossref_primary_10_1111_jnc_14055 crossref_primary_10_1016_j_sleep_2003_06_005 crossref_primary_10_1016_j_sleep_2015_05_021 crossref_primary_10_1016_j_pharmthera_2005_04_014 crossref_primary_10_1002_bdd_773 crossref_primary_10_1111_j_1742_1241_2001_tb11050_x crossref_primary_10_1016_S0140_6736_01_06656_9 crossref_primary_10_1056_NEJMra012893 crossref_primary_10_1053_smrv_2000_0126 crossref_primary_10_1080_10401230500464711 crossref_primary_10_2165_00002018_200528040_00003 crossref_primary_10_1002_hup_282 crossref_primary_10_1097_HTR_0b013e3181c1d1e1 crossref_primary_10_1097_00004714_200212000_00007 crossref_primary_10_1016_j_csm_2011_03_009 crossref_primary_10_2165_00044011_200525120_00002 crossref_primary_10_2165_00003088_200443040_00002 crossref_primary_10_2165_00023210_200519010_00008 crossref_primary_10_2165_00023210_200418050_00003 crossref_primary_10_1016_S0149_2918_00_83024_6 crossref_primary_10_1345_aph_1A086 crossref_primary_10_1053_jhep_2002_30957 crossref_primary_10_1345_aph_1A040 crossref_primary_10_1177_0269881109106898 crossref_primary_10_1016_S0749_0690_03_00044_2 crossref_primary_10_1177_0269881111408954 crossref_primary_10_1037_1064_1297_11_4_259 crossref_primary_10_2165_00002018_200326040_00004 crossref_primary_10_1185_030079908X273327 crossref_primary_10_1111_j_1365_2125_2008_03331_x crossref_primary_10_2165_00003495_200059040_00014 crossref_primary_10_1111_j_1742_1241_2001_tb10973_x crossref_primary_10_1093_sleep_zsy153 crossref_primary_10_1093_sleep_zsz241 crossref_primary_10_1016_S1389_9457_99_00006_4 crossref_primary_10_1517_14656566_5_7_1573 crossref_primary_10_2165_00023210_200013030_00005 crossref_primary_10_1517_13543784_9_4_841 crossref_primary_10_1002_hup_216 crossref_primary_10_1016_j_jsmc_2006_06_010 |
Cites_doi | 10.1097/00004714-199604000-00007 10.1016/S0009-9236(98)90139-4 10.1002/ddr.430330107 10.1007/BF02245455 10.1159/000137913 10.3928/0048-5713-19870701-06 10.1159/000137794 10.1017/S0033291700014379 10.1111/j.1365-2125.1990.tb03798.x 10.1016/0014-2999(96)00510-9 10.1093/sleep/14.5.408 10.2165/00003495-199040020-00008 10.1016/0924-9338(96)80094-0 10.3109/03602538308991391 10.1111/j.1471-4159.1984.tb09721.x 10.1111/j.1527-3458.1997.tb00324.x 10.1111/j.1365-2125.1980.tb01745.x 10.1002/j.1552-4604.1994.tb02002.x 10.1007/BF00735818 10.1007/BF00178503 10.1007/BF00265947 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS 1999 Blackwell Science Ltd 1999 |
Copyright_xml | – notice: 1999 INIST-CNRS – notice: 1999 Blackwell Science Ltd 1999 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.1046/j.1365-2125.1999.00024.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1365-2125 |
EndPage | 374 |
ExternalDocumentID | 10_1046_j_1365_2125_1999_00024_x 10510148 1922450 BCP024 |
Genre | article Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT 08R AAJUZ AAPBV AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS AKALU IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c5644-beaef6fa9188a26c3039076940355a08ce07040235a7db3a78e27a1c77dce87a3 |
IEDL.DBID | RPM |
ISSN | 0306-5251 |
IngestDate | Tue Sep 17 21:18:04 EDT 2024 Fri Aug 23 01:27:17 EDT 2024 Sat Nov 02 11:54:55 EDT 2024 Sun Oct 29 17:07:47 EDT 2023 Sat Aug 24 00:57:24 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Human Pharmacokinetic pharmacodynamic relationship Agonist Healthy subject Psychotropic Memory Gabaergic agonist Single dose Hypnotic Cognition Residual effect Blood Zaleplon Blood plasma Awakening Reaction time Zolpidem Clinical trial Response latency Sedative Pharmacokinetics Gabaergic receptor A Comparative study |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5644-beaef6fa9188a26c3039076940355a08ce07040235a7db3a78e27a1c77dce87a3 |
OpenAccessLink | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00024.x |
PMID | 10510148 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2014318 crossref_primary_10_1046_j_1365_2125_1999_00024_x pubmed_primary_10510148 pascalfrancis_primary_1922450 wiley_primary_10_1046_j_1365_2125_1999_00024_x_BCP024 |
PublicationCentury | 1900 |
PublicationDate | September 1999 |
PublicationDateYYYYMMDD | 1999-09-01 |
PublicationDate_xml | – month: 09 year: 1999 text: September 1999 |
PublicationDecade | 1990 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: London – name: England |
PublicationTitle | British journal of clinical pharmacology |
PublicationTitleAlternate | Br J Clin Pharmacol |
PublicationYear | 1999 |
Publisher | Blackwell Science Ltd Blackwell Science Blackwell Science Inc |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell Science – name: Blackwell Science Inc |
References | 1990; 30 1984; 42 1993; 45 1976; 47 1982; 17 1991; 14 1994; 114 1995; 10 1976 1969; 55 1995 1996; 13 1997; 3 1996; 16 1998; 21 1998; 64 1987; 17 1978; 8 1979 1983; 14 1996; 11 1990; 40 1986; 88 1991; 41 1980; 10 1987 1994; 34 1994; 33 1985 1996; 313 1983; 26 1983; 27 1989 e_1_2_5_26_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 Tobler I (e_1_2_5_34_2) 1991; 41 e_1_2_5_21_2 Berlin I (e_1_2_5_35_2) 1996; 13 e_1_2_5_28_2 e_1_2_5_29_2 Sternberg S (e_1_2_5_27_2) 1969; 55 Dement WC (e_1_2_5_2_2) 1982; 17 e_1_2_5_40_2 Fry J (e_1_2_5_39_2) 1998; 21 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_13_2 e_1_2_5_38_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_3_2 Johnson C (e_1_2_5_11_2) 1983; 26 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_19_2 e_1_2_5_30_2 Schechter BR (e_1_2_5_32_2) 1996; 11 |
References_xml | – volume: 88 start-page: 426 year: 1986 end-page: 433 article-title: Chronic use of benzodiazepines and psychomotor and cognitive test performance. publication-title: Psychopharmacology (Berl ) – start-page: 116 year: 1995 – volume: 27 start-page: 70 year: 1983 end-page: 75 article-title: Pharmacokinetics of benzodiazepine hypnotics. publication-title: Pharmacology – volume: 17 start-page: 446 year: 1987 end-page: 453 article-title: Epidemiology of sleep disorders. publication-title: Psychiatr Ann – volume: 3 start-page: 207 year: 1997 end-page: 224 article-title: A review of the preclinical development of Zaleplon, a novel non‐benzodiazepine hypnotic for the treatment of insomnia. publication-title: CNS Drug Reviews – volume: 11 start-page: 215 year: 1996 end-page: 305 article-title: Next day effects after night‐time treatment with zolpidem. publication-title: Eur J Psychiatry – start-page: 1257 year: 1979 end-page: 1262 – volume: 30 start-page: 463 year: 1990 end-page: 469 article-title: Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 20 mg and placebo. publication-title: Br J Clin Pharmacol – volume: 10 start-page: 189 year: 1980 end-page: 209 article-title: Psychomotor function and psychoactive drugs. publication-title: Br J Clin Pharmacol – volume: 55 start-page: 421 year: 1969 end-page: 457 article-title: Memory scanning: mental processes revealed by reaction time experience. publication-title: Am Sci – start-page: 1944 – volume: 42 start-page: 221 year: 1984 end-page: 229 article-title: Binding characteristics and interaction of depressant drugs with [35S]t‐butylbicyclophosphorothionate, a ligand that binds to the picrotoxin site. publication-title: J Neurochem – volume: 114 start-page: 138 year: 1994 end-page: 146 article-title: . EEG, profile of intravenous zolpidem in healthy volunteers. publication-title: Psychopharmacology (Berl ) – start-page: 239 year: 1976 end-page: 244 – volume: 8 start-page: 325 year: 1978 end-page: 329 article-title: Factor analysis of a sleep evaluation questionnaire. publication-title: Psychol med – volume: 33 start-page: 39 year: 1994 end-page: 45 article-title: CL 284, 846 [Zaleplon] a novel sedative–hypnotic. evaluation of its metabolites for pharmacological activity and . publication-title: Drug Dev Res – start-page: 339 year: 1985 end-page: 379 – start-page: 163 year: 1987 end-page: 172 – volume: 40 start-page: 291 year: 1990 end-page: 313 article-title: Zolpidem a review of its pharmacodynamic and pharmacokinetics properties and therapeutic potential. publication-title: Drugs – start-page: 265 year: 1987 end-page: 272 – volume: 14 start-page: 408 year: 1991 end-page: 413 article-title: Postmarketing surveillance of zopiclone insomnia: Analysis of 20.513 cases. publication-title: Sleep – volume: 45 start-page: 313 year: 1993 end-page: 320 article-title: The effects of single doses of CL 284, 846, lorazepam and placebo on psychomotor and memory function in normal male volunteers. publication-title: Eur J Clin Pharmacol – volume: 21 start-page: 262 year: 1998 article-title: . A phase III, 28‐day, multicenter, randomized, double‐blind comparator‐ and placebo‐controlled, parallel‐group safety, tolerability, and efficacy study of 5, 10, and 20 mg, of zaleplon, compared with 10 mg, of zolpidem or placebo, in adult outpatients with insomnia. publication-title: Sleep – volume: 14 start-page: 251 year: 1983 end-page: 292 article-title: Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. publication-title: Drug Metab Rev – volume: 47 start-page: 175 year: 1976 end-page: 182 article-title: Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects—a review. publication-title: Psychopharmacology – volume: 13 start-page: 100 year: 1996 end-page: 106 article-title: Comparisons of the effects of zolpidem and Triazolam on previous functions, psychomotor performances, and physical sway in healthy subjects. publication-title: J Clin Psychopharmacol – start-page: 313 year: 1989 end-page: 31 – volume: 313 start-page: 35 year: 1996 end-page: 42 article-title: Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem. publication-title: Eur J Pharmacol – volume: 10 start-page: 129 year: 1995 end-page: 135 article-title: Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunizatrepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. publication-title: Eur Psychiatry – volume: 26 start-page: 21 year: 1983 end-page: 137 article-title: Rebound insomnia and rebound anxiety: a review. publication-title: Pharmacology – start-page: 1537 year: 1985 end-page: 1553 – volume: 17 start-page: 3 year: 1982 end-page: 38 article-title: Rational basis for the use of sleeping pills. publication-title: Int Pharmacopsychiatry – volume: 16 start-page: 146 year: 1996 end-page: 157 article-title: Zolpidem, Triazolam and Temazepam: behavioural and subject related effects in normal volunteers. publication-title: J Clin Psychopharmacol – volume: 26 start-page: 21 year: 1983 end-page: 137 article-title: Sedative‐hypnotics and human performance. publication-title: Psychopharmacol – volume: 64 start-page: 553 year: 1998 end-page: 561 article-title: Comparative kinetics and dynamics of zaleplon, zolpidem and placebo. publication-title: Clin Parmacol Ther – volume: 34 start-page: 335 year: 1994 end-page: 344 article-title: . A placebo‐controlled evaluation of single, escalating doses of CL284, 846 (zaleplon), a non–benzodiazepine hypnotic. publication-title: J Clin Pharmacol – start-page: 1983 – volume: 41 start-page: 581 year: 1991 end-page: 583 article-title: Effects on night‐time motor activity and performance in the morning after midazolam intake during the night. publication-title: Arzneimittelforschung – volume: 11 start-page: 215 year: 1996 ident: e_1_2_5_32_2 article-title: Next day effects after night‐time treatment with zolpidem. publication-title: Eur J Psychiatry contributor: fullname: Schechter BR – volume: 13 start-page: 100 year: 1996 ident: e_1_2_5_35_2 article-title: Comparisons of the effects of zolpidem and Triazolam on previous functions, psychomotor performances, and physical sway in healthy subjects. publication-title: J Clin Psychopharmacol contributor: fullname: Berlin I – ident: e_1_2_5_36_2 doi: 10.1097/00004714-199604000-00007 – ident: e_1_2_5_30_2 doi: 10.1016/S0009-9236(98)90139-4 – ident: e_1_2_5_20_2 doi: 10.1002/ddr.430330107 – ident: e_1_2_5_16_2 – ident: e_1_2_5_10_2 – ident: e_1_2_5_13_2 – ident: e_1_2_5_33_2 doi: 10.1007/BF02245455 – ident: e_1_2_5_9_2 doi: 10.1159/000137913 – ident: e_1_2_5_8_2 – ident: e_1_2_5_3_2 – ident: e_1_2_5_5_2 doi: 10.3928/0048-5713-19870701-06 – ident: e_1_2_5_12_2 doi: 10.1159/000137794 – ident: e_1_2_5_21_2 – ident: e_1_2_5_28_2 doi: 10.1017/S0033291700014379 – ident: e_1_2_5_31_2 doi: 10.1111/j.1365-2125.1990.tb03798.x – ident: e_1_2_5_38_2 doi: 10.1016/0014-2999(96)00510-9 – ident: e_1_2_5_6_2 – ident: e_1_2_5_24_2 – ident: e_1_2_5_15_2 doi: 10.1093/sleep/14.5.408 – ident: e_1_2_5_22_2 doi: 10.2165/00003495-199040020-00008 – ident: e_1_2_5_40_2 – volume: 41 start-page: 581 year: 1991 ident: e_1_2_5_34_2 article-title: Effects on night‐time motor activity and performance in the morning after midazolam intake during the night. publication-title: Arzneimittelforschung contributor: fullname: Tobler I – ident: e_1_2_5_37_2 doi: 10.1016/0924-9338(96)80094-0 – ident: e_1_2_5_14_2 doi: 10.3109/03602538308991391 – volume: 55 start-page: 421 year: 1969 ident: e_1_2_5_27_2 article-title: Memory scanning: mental processes revealed by reaction time experience. publication-title: Am Sci contributor: fullname: Sternberg S – ident: e_1_2_5_17_2 doi: 10.1111/j.1471-4159.1984.tb09721.x – volume: 21 start-page: 262 year: 1998 ident: e_1_2_5_39_2 article-title: . A phase III, 28‐day, multicenter, randomized, double‐blind comparator‐ and placebo‐controlled, parallel‐group safety, tolerability, and efficacy study of 5, 10, and 20 mg, of zaleplon, compared with 10 mg, of zolpidem or placebo, in adult outpatients with insomnia. publication-title: Sleep contributor: fullname: Fry J – ident: e_1_2_5_18_2 doi: 10.1111/j.1527-3458.1997.tb00324.x – ident: e_1_2_5_23_2 doi: 10.1111/j.1365-2125.1980.tb01745.x – volume: 26 start-page: 21 year: 1983 ident: e_1_2_5_11_2 article-title: Sedative‐hypnotics and human performance. publication-title: Psychopharmacol contributor: fullname: Johnson C – ident: e_1_2_5_19_2 doi: 10.1002/j.1552-4604.1994.tb02002.x – ident: e_1_2_5_26_2 doi: 10.1007/BF00735818 – ident: e_1_2_5_7_2 – ident: e_1_2_5_25_2 doi: 10.1007/BF00178503 – ident: e_1_2_5_29_2 doi: 10.1007/BF00265947 – ident: e_1_2_5_4_2 – volume: 17 start-page: 3 year: 1982 ident: e_1_2_5_2_2 article-title: Rational basis for the use of sleeping pills. publication-title: Int Pharmacopsychiatry contributor: fullname: Dement WC |
SSID | ssj0013165 |
Score | 1.9945704 |
Snippet | Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at... To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration at... Aims To compare the duration of the residual hypnotic and sedative effects of zaleplon with those of zolpidem and placebo following nocturnal administration... |
SourceID | pubmedcentral crossref pubmed pascalfrancis wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 367 |
SubjectTerms | Acetamides - administration & dosage Acetamides - adverse effects Adult Biological and medical sciences Double-Blind Method Drug Administration Schedule Female Humans hypnotic Hypnotics and Sedatives - administration & dosage Hypnotics and Sedatives - adverse effects Hypnotics. Sedatives Male Medical sciences Memory - drug effects Neuropharmacology Original Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychomotor Performance - drug effects Psychopharmacology Pyridines - administration & dosage Pyridines - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects residual effects sedative zaleplon Zolpidem |
SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp0Lp-7FJE3QoOcXLypYs-5imCaHQspQEcjMjWSJlg70kG9LsKZB_ml_SGcn7cOihlN6MbfkxHmk-Wd98w9gnYQqT-8wkdS0hkTXIxJROJMYaK4H0TizlDn_7nh-fyq9n6qzjP1EuTNSHWP5wo54Rxmvq4GBiFZJRULddMLQwQlPKHclOYrwZEp4UmSZ215cf6WpBQYSqkoSQce6lREfq6RY4_3ihXqR6NoUrNJqP1S7WwtVjKuU6xA0x6ugFmyzeLlJTJsPrmRna-SPhx__z-i_Z8w7K8v3oe6_YE9e8ZrvjqIV9u8dPVqldV3t8l49XKtm3b9jlPrfLGoi89RyRKMe5f0gO4x3NhPbPMYRNL_AcaGo-by9CSVvu0X_bG4y7HHryv1zxWcvTh7v7c24cInLH4QYmjn7_vGWnR4cnB8dJVwAisQpxWmIcOJ97KEVRQJpbDLc4l89LOUKUBKPCOhywJCn2gK5NBrpwqQZhtcbvUWjI3rGNpm3cB8al0cpnVpnAbLWqdLrIc5zr-Qw8pMWAicXHrqZR56MK6_OSctnI1BWZuiJTV8HU1a8B2-55xaphicBIjQbsfXSOtSvSECjxbrrnNssTSOy7f6T5eR5Ev1MSYhTYUgWv-OuHrD4fjHFj8x_bbbGnUaiCWHUf2cbs8tptIwybmZ3QwX4D-0woag priority: 102 providerName: Wiley-Blackwell |
Title | A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2125.1999.00024.x https://www.ncbi.nlm.nih.gov/pubmed/10510148 https://pubmed.ncbi.nlm.nih.gov/PMC2014318 |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEB2SnAql9LtqmjCHklMUW9KuVjqmpiEUUkxJIDcxu9oloY4kGpd8_PrOrqTY7qn0ZmTJFvvGnjfaN28APie60LnLdFzXgmJRk4h1aZNYG20Eeb8T43uHz77npxfi26W83AI59sIE0b7R10fN4uaoub4K2sruxkxGndhkfjZLvSldUky2YZsDdCzRx62DJMyP9FyYqyyZDPKdYSsziLo4qfsuPe9UySmq96IOwemnAK2lp-cd3fJKuX7ExVqO-ls_uc5rQ2I6eQkvBkaJx_2dv4It27yGg3lvSf1wiOerDqvbQzzA-cqs-uENdMdonkYRYuuQCSFyCR56tHBQe_jjj5xJugWfQ02Nj-0iTJZFx2HU3nH6Q9pw4UWJyxZTvEJtmRZbpDv6af0zmLdwcfL1fHYaD1MYYiOZLMXaknW5ozIpCkpzwzmPC-q8FFOmKjQtjOV_DeFtc0jVOiNV2FRRYpTi9SkUZe9gp2kb-wFQaCVdZqQO8lIjS6uKPOeCy2XkKC0iSMbFr7rebKMKm-TCN5R57CqPXeWxqwJ21X0EexsorS4smZ3IaQTve7DWPrGHOgK1AePTCd5xe_MdDsTgvD0EXgQyAP7PN1l9mc35xcf__sZdeNb7RXhx2yfYWf76bfeYDS31PtcBP9L98Bv4A0fKB2g |
link.rule.ids | 230,315,730,783,787,888,1378,27938,27939,46308,46732,53806,53808 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEB1Remilqt-0ptDOoeKEk_hj7fURoqK0JSiHUHGzdtdrgQi2VYIo-fXM7tok4dT2Zvkz9j573mTfvAH4GkgukzKSflHEwo8LEfsy04EvlVSxMH4nytQOj0-S0Wn844ydbQDramGsaF_Ji141u-pVF-dWW9lcqX6nE-tPxsPQmNIFvP8EntL7Oki6JL2bPAhsB0nDhinPYkEr4GknM62si8K6qdMzXpUUpJwbtYWn6QO0EqBeNOKanlXpmlysRKnHCspVZmtD09Er-NXdlFOkXPZu5rKnFo_8Hv_5rl_Dy5as4oHb_AY2dPUW9ibO7fpuH6fL4q3rfdzDydIH--4dNAeoHrocYl0icU2k7N6Wf2ErJDHrFxSkmhntI6oCF_XMNq3FkhBa31JkRbFm8IsM5zWGeI5SE-PWKG7FpTZ_77yH06Nv0-HIbxs8-IoRD_OlFrpMSpEFnIswURROKVdPsnhALEgMuNL0QYqNI49ICxmJlOswFYFKU3rwPBXRFmxWdaU_AsYyZWWkmLTKVcUynfIkoVyujEQpQu5B0I1q3jgfj9zOv8emVs2AIjegyA0ocguK_I8Hu2vDvzwwI-LDBh58cChYOaPDkAfpGj4edjBm3utbaLStqXc7uh4wi6S__pH54XBCC9v_fcUv8Gw0HR_nx99Pfn6C586WwmjodmBz_vtG7xLpmsvP9hW7B7jFKGo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb5tAEB21qVRVqtLvlrZp51DlFGwDCyzH1K2VfiTikEhRL2h32VWiOIASR2n86zu7QIxzqnJDZm0-9sG88b55A_AlkFwmJpJ-WTLhs1IwX2Y68KWSignrd6Js7fD-QbJ3xH4ex8eDVl9OtK_k6aian4-q0xOnrWzO1bjXiY3z_WloTekCPm5KM34Ij-iZnfA-Ue8XEALXRdIyYsq14qAT8XQLmk7aRaHd1upZv0oKVK0jtYOo7QU0CFJPG3FJ98u0jS4GkequinLIbl14mj2DP_2FtaqUs9HVQo7U8o7n472u_DlsdqQVd9shL-CBrl7Cdt66Xt_s4OGqiOtyB7cxX_lh37yCZhfVbbdDrA0S50TK8l0ZGHaCEvv5koJVM6cxoipxWc9d81o0hNT6miIsijWjX4xxUWOIJyg1MW-N4lqcafs3z2s4mn0_nO75XaMHX8XEx3yphTaJEVnAuQgTRWGVcvYkYxNiQ2LClaYXE7POPCItZSRSrsNUBCpN6ebzVERvYKOqK_0OkMk0NpGKpVOwqjjTKU8SyulMJIwIuQdBP7NF0_p5FG4dntmaNQuMwgKjsMAoHDCKvx5srUFg9cWMCFA88eBti4TBL7Y48iBdw8jtAGvqvb6HZtyZe3cz7EHs0PTfJ1l8nea08f7eR_wMj_Nvs-L3j4NfH-BJ605hpXQfYWNxcaW3iHst5Cf3lP0DFSgq6g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comparison+of+the+residual+effects+of+zaleplon+and+zolpidem+following+administration+5+to+2+h+before+awakening&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Danjou%2C+P&rft.au=Paty%2C+I&rft.au=Fruncillo%2C+R&rft.au=Worthington%2C+P&rft.date=1999-09-01&rft.issn=0306-5251&rft.volume=48&rft.issue=3&rft.spage=367&rft_id=info:doi/10.1046%2Fj.1365-2125.1999.00024.x&rft_id=info%3Apmid%2F10510148&rft.externalDocID=10510148 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |